Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PACERONE vs TAMBOCOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
Life-threatening recurrent ventricular arrhythmias (e.g., ventricular fibrillation, hemodynamically unstable ventricular tachycardia),Atrial fibrillation and atrial flutter (off-label may include maintenance of sinus rhythm)
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter (off-label)
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (Cr Cl < 35 m L/min).
Primarily hepatic via CYP3A4 and CYP2C8; active metabolite desethylamiodarone; substrate of P-glycoprotein.
Hepatic metabolism via CYP2D6; active metabolite; renal excretion of unchanged drug and metabolites.
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
96% bound, primarily to albumin and beta-lipoproteins.
90–95% bound to albumin and alpha-1-acid glycoprotein.
66 L/kg (range 10-200 L/kg) indicating extensive tissue distribution, especially in adipose tissue, liver, and lungs.
8–10 L/kg; extensive tissue distribution (lung, heart, liver).
Oral: 30-80% (mean ~50%), increased by food; erratic absorption due to high lipophilicity. IV: 100%.
Oral: 85–90% (first-pass metabolism minimal).
No specific GFR-based dose adjustment required; caution in severe renal impairment due to possible accumulation of active metabolite desethylamiodarone. Monitor serum levels and QT interval.
Cr Cl >50 m L/min: no adjustment; Cr Cl 35-50 m L/min: 50 mg every 12 hours; Cr Cl <35 m L/min: 100 mg every 24 hours or 50 mg every 12 hours with caution.
Contraindicated in severe hepatic disease (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce maintenance dose by 50% and monitor liver function. Mild impairment (Child-Pugh A): no adjustment, but monitor.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25-50%; Child-Pugh class C: contraindicated or use with extreme caution.
Loading: 10-20 mg/kg/day PO in divided doses for 7-10 days; maintenance: 5-10 mg/kg/day PO once daily. IV loading: 5 mg/kg over 30 min, then 5-15 mg/kg/day continuous infusion.
Dosing not established; limited data: 1-3 mg/kg/day orally divided every 8-12 hours; maximum 6 mg/kg/day.
Lower maintenance doses (100-200 mg/day PO) due to increased risk of bradycardia, QT prolongation, and thyroid dysfunction. Monitor renal function and electrolytes closely.
Start at 50 mg every 12 hours; increase slowly with close monitoring of plasma levels and ECG; consider lower doses due to reduced renal function.
Only for patients with life-threatening arrhythmias due to risk of pulmonary toxicity, hepatotoxicity, and proarrhythmia; requires baseline and periodic monitoring of pulmonary function, liver enzymes, thyroid function, and ECG.
May increase mortality in patients with structural heart disease (e.g., post-MI, cardiomyopathy). Reserved for life-threatening arrhythmias.
Pulmonary toxicity (interstitial pneumonitis, pulmonary fibrosis), hepatotoxicity (elevated liver enzymes, hepatic failure), proarrhythmia (worsening arrhythmias, torsades de pointes), thyroid dysfunction (hypo- or hyperthyroidism), optic neuropathy/neuritis, skin discoloration, photosensitivity, bradycardia, and drug interactions (CYP450 and P-gp mediated).
Proarrhythmic effects including new or worsened ventricular arrhythmias,Use caution in patients with conduction abnormalities (e.g., SA node dysfunction, bundle branch block),Heart failure exacerbation due to negative inotropic effects,Electrolyte disturbances (hypokalemia, hypomagnesemia) should be corrected,Plasma monitoring recommended due to narrow therapeutic index
Cardiogenic shock, severe sinus node dysfunction (without pacemaker), second- or third-degree AV block (without pacemaker), marked bradycardia, and hypersensitivity to amiodarone or iodine.
Second- or third-degree AV block (unless pacemaker in place),Bifascicular block or distal conduction blocks,Cardiogenic shock or severe hypotension,Pre-existing prolonged QT interval,History of ventricular arrhythmias associated with structural heart disease
Avoid grapefruit juice as it inhibits CYP3A4 and can increase amiodarone levels. St. John's wort may decrease amiodarone efficacy by inducing metabolism. Take with food to reduce gastrointestinal irritation.
Grapefruit juice increases flecainide AUC by 15-40% and should be avoided. High-fat meals may delay absorption but do not significantly alter overall exposure. No other specific dietary restrictions.
Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine content. Second and third trimesters: continued risk of fetal hypothyroidism and bradycardia; neonatal monitoring for thyroid function and ECG is recommended.
FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trimesters: Risk of fetal arrhythmia, including tachycardia or heart block; may require fetal echocardiography. Avoid in pregnancy unless benefit outweighs risk.
Amiodarone is excreted into breast milk with an M/P ratio of approximately 0.1-1.0. Due to significant accumulation in infant tissues and long half-life, breastfeeding is contraindicated because of potential for neonatal hypothyroidism and bradycardia.
Flecainide is excreted into breast milk. Milk-to-plasma ratio approximately 2.5 (range 1.4–3.8). Infant exposure estimated at 3–5% of maternal weight-adjusted dose. Monitor infant for bradycardia, arrhythmia, and feeding difficulties. Use with caution; alternative agents preferred.
Pregnancy increases volume of distribution and clearance of amiodarone, potentially requiring dose adjustments to maintain therapeutic levels. However, due to risks, use is limited to severe arrhythmias and doses should be minimized. Monitoring of serum levels is recommended to guide dosing.
Increased plasma volume and renal clearance in pregnancy may reduce flecainide levels. Monitor therapeutic drug levels and ECG; dose adjustments may be needed (typically increased dose required). Titrate based on arrhythmia control and toxicity. Postpartum: dose may need reduction as clearance normalizes.
Amiodarone has an extremely long half-life (up to 107 days) causing delayed onset and prolonged effects. Monitor for thyroid dysfunction, pulmonary fibrosis, liver toxicity, and corneal deposits. Avoid coadministration with drugs prolonging QT interval. Use lowest effective dose due to cumulative toxicity.
Tambocor (flecainide) is a class Ic antiarrhythmic used for life-threatening ventricular arrhythmias and paroxysmal atrial fibrillation/flutter. It has a narrow therapeutic index and requires ECG monitoring for QRS prolongation (>140 ms) or new arrhythmias. Contraindicated in ischemic heart disease due to increased mortality (CAST trial). Adjust dose in renal impairment (Cr Cl < 50 m L/min: start at 50 mg q12h). Proarrhythmic risk is highest in patients with structural heart disease or reduced EF. Monitor trough levels (therapeutic range: 0.2-1.0 mcg/m L).
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations.,Inform your doctor if you experience vision changes, thyroid symptoms (weight change, heat/cold intolerance), or skin discoloration.,Avoid grapefruit juice and St. John's wort as they may affect drug levels.,Use sun protection; amiodarone increases sun sensitivity.,Do not breastfeed while taking this medication.,Keep all follow-up appointments for blood tests, eye exams, and lung function tests.,This medication can cause birth defects; use effective contraception.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Report any new or worsening chest pain, palpitations, fainting, or difficulty breathing immediately.,Avoid grapefruit juice as it can increase flecainide levels and risk of side effects.,Take with or without food; maintain consistent timing to keep levels stable.,Do not crush or chew extended-release capsules; swallow whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PACERONE vs TAMBOCOR, answered by our medical review team.
PACERONE is a Antiarrhythmic Agent that works by Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.. TAMBOCOR is a Antiarrhythmic Agent that works by Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PACERONE and TAMBOCOR depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PACERONE is: Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.. The standard adult dose of TAMBOCOR is: For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PACERONE and TAMBOCOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PACERONE is classified as Category C. Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine conte. TAMBOCOR is classified as Category C. FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.